Business Context and Reporting Period
Company: Church & Dwight Co., Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 1, 2005
Business Overview: The Company operates in three segments: Consumer Domestic (deodorizing, cleaning, laundry, personal care), Consumer International (personal care), and Specialty Products Division (SPD). A significant event impacting this period is the full consolidation of Armkel, LLC, following the purchase of the remaining 50% interest on May 28, 2004. Results for Armkel are fully included in the 2005 figures, whereas only equity earnings were recorded in the comparable 2004 period.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2005 | Q1 2004 |
|---|---|---|
| Net Sales | $420,674 | $295,991 |
| Gross Profit | $160,237 | $96,562 |
| Gross Margin | 38.1% | 32.6% |
| Income from Operations | $67,152 | $38,460 |
| Net Income | $37,701 | $29,906 |
| Diluted EPS | $0.56 | $0.46 |
| Operating Cash Flow | $31,161 | $31,111 |
| Total Debt (Short + Long Term) | $790,500 | $858,700 (Dec 31, 2004) |
| Cash and Equivalents | $101,902 | $145,540 (Dec 31, 2004) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 42.1% ($124.7 million). Approximately $122.6 million of this increase is attributable to the consolidation of Armkel sales, which were previously recorded under the equity method.
- Profitability: Gross margin improved to 38.1% from 32.6%, driven by the inclusion of Armkel products which carry higher margins. Excluding Armkel, organic gross margins declined due to rising oil-based raw material and packaging costs.
- Expenses: Marketing expenses rose $13.5 million and SG&A expenses rose $21.5 million, primarily due to the integration of Armkel operations. However, non-Armkel SG&A costs decreased due to lower deferred compensation and Sarbanes-Oxley compliance costs.
- Debt Reduction: Total debt decreased by approximately $68.2 million from year-end 2004, driven by voluntary repayments of $75.0 million on the Term B Loan.
- Equity Earnings: Equity in earnings of affiliates dropped $8.6 million because the Company now consolidates Armkel rather than recording equity income.
Outlook, Risks, and Management Commentary
- Cost Pressures: Management notes sharp price increases for oil-based raw materials and commodity chemicals. The Company is implementing cost reduction programs in formulation, packaging, and logistics to mitigate margin erosion.
- Regulatory Risks: The Company faces potential FDA guidance regarding the labeling of condoms containing nonoxynol-9 (N-9). While interim labeling changes have been made, future restrictions could impact financial results.
- Liquidity and Covenants: Adjusted EBITDA for the quarter was approximately $79.5 million. The Company is well within its credit facility covenants, with a leverage ratio of 2.74 (limit 4.25) and an interest coverage ratio of 5.44 (minimum 3.0).
- Accounting Changes: The Company is evaluating the impact of the American Jobs Creation Act of 2004 on foreign earnings repatriation and will adopt SFAS No. 123R (share-based payment) effective January 1, 2006.
- Asset Sales: The Company expects to close on the sale of land in Cranbury, NJ, and has already sold a manufacturing plant in Mexico for approximately $2.3 million net.
Investor Verification Checklist
- Armkel Integration: Verify the sustainability of the gross margin expansion (38.1%) once the one-time benefit of consolidating Armkel is normalized against rising commodity costs.
- Debt Servicing: Confirm the impact of the $75 million voluntary debt repayment on future liquidity and interest expense coverage.
- Regulatory Exposure: Monitor FDA developments regarding N-9 labeling requirements and their potential impact on the Trojan brand revenue.
- Working Capital: Review the $22.7 million increase in working capital and other liabilities affecting operating cash flow.
- Stock-Based Compensation: Note the pro forma impact of SFAS 123R adoption in 2006, which would reduce reported net income by approximately $1.1 million for the quarter.